If you displayed patience with Cardinal Health's shares (CAH), first discussed here on April 21, 2009, at a pre-spin-off price of $34.22, over the past three months, you've been rewarded. Cardinal has soared past $40 resistance, after meandering in the low $30s for about nine months.

Cardinal probably will post a 3% to 5% 2011 revenue rise, after a 1.4% dip in 2010.

Key operation factors working in Cardinal's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.

Cardinal Health's shares (CAH), first discussed here on April 27, 2009, at a pre-spin-off price of $34.22, continued to meander over the past four months, but I still like the business model at this juncture. Here's why.

Cardinal probably will post a 3% to 5% 2010 revenue rise, followed by a 2% to 4% increase in 2011.

Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.

Analyst Upgrades

• JPMorgan upgraded Vivus (VVUS) to overweight from neutral.
• Citigroup upgraded Corn Products (CPO) to buy from hold.
• Maxim Integrated (MXIM) was upgraded to outperform from market perform at FBR Capital.
• Cardinal Health (CAH) was upgraded to outperform from neutral at RW Baird.
• Citigroup upgraded Monster Worldwide (MWW) and EchoStar (SATS) to buy from hold, as well as Las Vegas Sands (LVS) to buy from sell.
• BMO Capital upgraded Potash (POT) and Barrick Gold (ABX) to outperform from market perform.

Analyst Upgrades

• Amazon.com (AMZN) was upgraded to buy from neutral at BofA/Merrill.
• Netflix (NFLX) was upgraded to outperform from perform at Oppenheimer and to neutral from sell at Janney Montgomery.
• Janney Montgomery also upgraded BJ's Wholesale (BJ) to buy from neutral.
• RW Baird upgraded Kforce.com (KFRC), SFN Group (SFN) and Young Innovations (YDNT) to outperform from neutral.
• NetSuite (N) was upgraded to neutral from underweight and Select Comfort (SCSS) was upgraded to overweight from neutral at Piper Jaffray.
• Flushing Financial (FFIC) was upgraded to outperform from market perform at Keefe Bruyette.
• National Instruments (NATI) was upgraded to buy from hold at Stifel Nicolaus.
• RBC Capital upgraded MDS Inc. (MDZ) to outperform from sector perform.

The shares of Cardinal Health (CAH) have meandered the past three months, but investors should view that sideways action as an extended opportunity to scoop-up shares, as the pleasant story continues with CAH.

Cardinal Health spun-off 81% of its clinical and medical products segment, CareFusion Corp. (CFN) in August 2009.

First discussed here on April 17, 2009 at a pre-spin-off price of $34.22, Cardinal's outlook is promising, due to a likely 3-5% 2010 revenue rise, after a 2.9% increase in 2009.

Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls.

The positive story continues with Cardinal Health (CAH), which spun-off 81% of its clinical and medical products segment, CareFusion Corp. (CFN), in August 2009.

I first discussed Cardinal Health as a potential buy at a pre-spin-off price of $34.22, Cardinal's stock has since returned to the $35-range, on a likely 3% to 5% 2010 revenue rise.

Key operational factors working in CAH's favor include increased prescription sales, modest price power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls.

Cardinal Health (CAH) spun-off 81% its clinical and medical products segment, CareFusion Corp. (CFN) in August 2009, hence an asset-adjusted CAH review is in order.

Look for CAH's 2010 revenue to increase 3.5-5%, boosted by increased prescription sales, lower customer attrition, and better performance of wider-margin generic drugs.

It's a difficult call, but I'm Reiterating my Buy rating for Cardinal Health (NYSE: CAH), first recommended on April 21, 2009 at a price of $33.52.

Cardinal Health has meandered since April, despite generally favorable investor reviews of CAH's plan to spin-off its clinical medical products segment in mid-2009, to be called CareFusion Corp., allowing Cardinal to focus on revitalizing its health care supply chain services business, which recently returned to profitability.

It goes without saying that this market remains a stock picker's market. Select the wrong stock, and there's a 30-40% haircut up ahead; select the correct stock, and you're positioned for the recovery with modest downside exposure. For a chance at the latter, consider Cardinal Health (NYSE: CAH).

In general, analysts view CAH's filing to spin-off its clinical medical products segment in mid-2009 as allowing Cardinal to focus on revitalizing its health care supply chain services business, which recently returned to profitability.

Hansen Medical (NASDAQ: HNSN) said economic conditions have led to lower than expected Q4 sales. HNSN, a developer of products for robotic catheter-based technologies, closed at $6.26. Thomas Weisel Partners has a $8 price target on HNSN. HNSN February call option implied volatility is at 115, puts are at 133, above its 26-week average of 69, according to Track Data, suggesting larger price movement.

Cardinal Health (NYSE: CAH), a drug wholesaler and medical-equipment supplier, lowered its full-year outlook on January 8 because it sees reduced hospital spending. Smith Barney has a 12-month price target of $39 on CAH. February option implied volatility of 49 is above its 26-week average of 41 according to Track Data, suggesting larger price movement.

Becton Dickinson (NYSE: BDX), a medical technology company, closed at $69.11. Morgan Stanley raised its rating on BDX to Overweight. BDX February option implied volatility of 38 is above its 26-week average of 33, according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.

"Should Obama win the election, we would look towards select sub-sectors of health care; one stock we would expect to benefit is health supply distributor, Cardinal Health (NYSE: CAH)," explains Kelley Wright, editor of the blue chip Investment Quality Trends.

"A President Obama will have to make good on his promise to deliver better health care. While this could create havoc for the pharmaceutical producers, drug therapies and medical supplies will have to be delivered.

"The 800lb. gorilla in the supply and distribution space is Cardinal Health. Cardinal is a global company whose distribution businesses consolidate pharmaceuticals and medical products from thousands of manufacturers into site-specific deliveries to retail pharmacies, hospitals, physician's offices, surgery centers and alternate care facilities.

"The company has recently taken steps to increase the percentage of cash flow into dividends and share repurchases to enhance shareholder value.

"The blue chip stocks that we recommend are chosen for the exemplary long-term dividend growth, a P/E ratio of 15 or less, a payout ratio of 50% or less, debt of 50% or less, and technical characteristics on the daily and weekly charts that suggests the potential for imminent capital appreciation.

"While the current dividend yield on Cardinal Health is comparatively low at around 1.0%, the upside potential for capital appreciation is quite large."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

This post is part of a series in which TheStockAdvisors.com asked financial experts to name their top stock pick if McCain or if Obama wins the election.

Which stocks would benefit from a victory by either Senator John McCain or Senator Barack Obama? To help investors sort through the sectors and stocks best positioned to benefit in a post-election environment, we posed this question to some of the nation's leading financial newsletter advisors.

Importantly, this is not a partisan report; each participating advisor has provided a favorite stock for both candidates, focused not on political preferences but unbiased stock analysis. Below we feature those stocks and ETFs that the advisors believe will be the winners depending on which candidate prevails.

McCain Stocks:

Roger Conrad - Comcast (NYSE: CCW)
Gregg Early - Elbit Systems (NASDAQ: ESLT)
Elliott Gue - Paladin Resources (Toronto: PDN)
Doug Fabian - Market Vectors Nuclear Energy (NYSE: NLR)
Vivian Lewis - Barclays (NYSE: BCS)
Bill Martin - CGG Veritas (NYSE: CGV)'
Yiannis Mostrous - Lonking Holdings (OTC: CIMHF)
Carla Pasternak - Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT)
Nate Pile - SPDR Gold Trust (NYSE: GLD)
John Reese - General Dynamics (NYSE: GD)
Nathan Slaughter - USEC (NYSE: USU)
Paul Tracy - Shaw Group (NYSE: SGR)
Kelley Wright - CenturyTel (NYSE: CTL)
Tom Vass - Molex (NASDAQ: MOLX)
Martin Hutchinson - Northrop Grumman (NYSE: NOC), Merck & Co. (NYSE: MRK), EOG Resources (NYSE: EOG)

Obama Stocks:

Roger Conrad - SunPower (NASDAQ: SPWR)
Gregg Early - AeroVironment (NASDAQ: AVAV)
Elliott Gue - SunPower (NASDAQ: SPWR)
Doug Fabian - Industrial Select Sector SPDR (NYSE: XLI)
Vivian Lewis - Cosan (NYSE: CZZ)
Bill Martin - Geron (NASDAQ: GERN)
Yiannis Mostrous - Dr. Reddy's (NYSE: RDY)
Carla Pasternak - Kinder Morgan Energy Partners (NYSE: KMP)
Nate Pile - Apple (NASDAQ: AAPL)
John Reese - American Eagle (NYSE: AEO)
Nathan Slaughter - Fluor (NYSE: FLR)
Paul Tracy - Market Vectors Global Alternative Energy (NYSE: GEX)
Kelley Wright - Cardinal Health (NYSE: CAH)
Tom Vass - Ingersoll Rand (NYSE: IR)
Martin Hutchinson - Microsoft (NASDAQ: MSFT), Time Warner Inc. (NYSE: TWX), First Solar (NASDAQ: FSLR)

MOST NOTEWORTHY: WuXi Pharma, ExxonMobil and LifePoint Hospitals were today's noteworthy upgrades:

• Jefferies upgraded shares of WuXi Pharma (NYSE: WX) to Buy from Hold as they believe the risk/reward is much improved following the recent weakness. They think the company's 2008 guidance is achievable.
  
• Credit Suisse raised ExxonMobil (NYSE: XOM) to Outperform from Neutral as they believe the rise in crude oil means analyst estimates are too low.
  
• Goldman sees upside to hospital stocks given low valuations and expectations. The firm upgraded LifePoint Hospitals (NASDAQ: LPNT) to Buy from Neutral and named it a top pick along with previous top pick Cardinal Health (NYSE: CAH).

OTHER UPGRADES:

• Goldman added NDS Group (NASDAQ: NNDS) to their Conviction Buy List and upgraded shares to Buy from Neutral.
  
• Morgan Stanley raised Boeing (NYSE: BA) to Overweight from Equal Weight.
  
• JP Morgan added Sherwin-Williams (NYSE: SHW) to the Focus List.

MOST NOTEWORTHY: DiamondRock Hospitality, Pzena Investment and Vodafone were today's noteworthy upgrades:

• DiamondRock Hospitality (NYSE: DRH) was upgraded to Outperform from Neutral at Baird, citing the newly-announced 4.8M repurchase plan, strong balance sheet and valuation.
  
• Keefe Bruyette upgraded shares of Pzena Investment (NYSE: PZN) to Market Perform from Underperform after the company announced February ending AUM.
  
• Goldman added Vodafone (NYSE: VOD) to its Conviction Buy List following the recent weakness as they expect the company to benefit from growth in wireless data.

OTHER UPGRADES:

• UBS raised Weyerhaeuser (NYSE: WY) to Buy from Neutral.
  
• Credit Suisse upgraded MedCath (NASDAQ: MDTH) and Lululemon (NASDAQ: LULU) to Outperform from Neutral.
  
• Goldman added Cardinal Health (NYSE: CAH) to its Conviction Buy List.

MOST NOTEWORTHY: Washington Post, Harvest Natural, Memc Electronic Materials and Boston Private Financial were today's noteworthy upgrades:

• Deutsche Bank upgraded shares of The Washington Post Company (NYSE: WPO to Buy from Hold to reflect the company's exposure to the counter-cyclical education division.
• Jefferies upgraded shares of Harvest Natural Resources Inc. (NYSE: HNR) to Buy from Hold and raised their target to $17 from $11 after the company received final approval in the conversion to a mixed company. They note that conversion clears the way for renewed investment.
• Friedman Billings added Memc Electronic Materials Inc (NYSE: WFR) to its Top Picks List following its Q3 report and guidance as "solar wafer contracts," not including spot poly, are expected to increase from 15% of the total to 35%-40% in CY08 and greater than 50% in CY09.
• William Blair raised its rating on Boston Private Financial Holdings Inc (NASDAQ: BPFH) to Outperform from Market Perform after the better-than-expected Q3 results.

OTHER UPGRADES:

• Goldman added Dell Inc (NASDAQ: DELL) to its Conviction Buy List.
• NTT DoCoMo Inc (NYSE: DCM) was upgraded to Hold from Sell at Citigroup and to Buy from Neutral at UBS.
• Credit Suisse upgraded Cardinal Health Incorporated (NYSE: CAH) to Outperform from Neutral.
• Merrill upgraded Coca-Cola Femsa SA (NYSE: KOF) and Northeast Utilities (NYSE: NU) to Buy from Neutral.